Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Found 1 result for Treated hydrocephalus in individuals with myelomeningocele in the National Spina Bifida Patient Registry
Filters applied. Clear filters
. 2018 Dec 1;22(6):646-651.
doi: 10.3171/2018.5.PEDS18161. Epub 2018 Aug 24.

Treated hydrocephalus in individuals with myelomeningocele in the National Spina Bifida Patient Registry

Irene Kim  1 , Betsy Hopson  2 , Inmaculada Aban  3 , Elias B Rizk  4 , Mark S Dias  4 , Robin Bowman  5 , Laurie L Ackerman  6 , Michael D Partington  7 , Heidi Castillo  8 , Jonathan Castillo  8 , Paula R Peterson  9 , Jeffrey P Blount  2 , Brandon G Rocque  2
Affiliations

Treated hydrocephalus in individuals with myelomeningocele in the National Spina Bifida Patient Registry

Irene Kim et al. J Neurosurg Pediatr. .

Abstract

OBJECTIVEAlthough the majority of patients with myelomeningocele have hydrocephalus, reported rates of hydrocephalus treatment vary widely. The purpose of this study was to determine the rate of surgical treatment for hydrocephalus in patients with myelomeningocele in the National Spina Bifida Patient Registry (NSBPR). In addition, the authors explored the variation in shunting rates across NSBPR institutions, examined the relationship between hydrocephalus, and the functional lesion level of the myelomeningocele, and evaluated for temporal trends in rates of treated hydrocephalus.METHODSThe authors queried the NSBPR to identify all patients with myelomeningoceles. Individuals were identified as having been treated for hydrocephalus if they had undergone at least 1 hydrocephalus-related operation. For each participating NSBPR institution, the authors calculated the proportion of patients with treated hydrocephalus who were enrolled at that site. Logistic regression was performed to analyze the relationship between hydrocephalus and the functional lesion level of the myelomeningocele and to compare the rate of treated hydrocephalus in children born before 2005 with those born in 2005 or later.RESULTSA total of 4448 patients with myelomeningocele were identified from 26 institutions, of whom 3558 patients (79.99%) had undergone at least 1 hydrocephalus-related operation. The rate of treated hydrocephalus ranged from 72% to 96% among institutions enrolling more than 10 patients. This difference in treatment rates between centers was statistically significant (p < 0.001). Insufficient data were available in the NSBPR to analyze reasons for the different rates of hydrocephalus treatment between sites. Multivariate logistic regression demonstrated that more rostral functional lesion levels were associated with higher rates of treated hydrocephalus (p < 0.001) but demonstrated no significant difference in hydrocephalus treatment rates between children born before versus after 2005.CONCLUSIONSThe rate of hydrocephalus treatment in patients with myelomeningocele in the NSBPR is 79.99%, which is consistent with the rates in previously published literature. The authors' data demonstrate a clear association between functional lesion level of the myelomeningocele and the need for hydrocephalus treatment.

Keywords: CDC = Centers for Disease Control and Prevention; MOMS = Management of Myelomeningocele Study; NSBPR = National Spina Bifida Patient Registry; VP shunt; congenital; hydrocephalus; myelomeningocele; spina bifida.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Age of included patients
Figure 2.
Figure 2.
Distribution of treated hydrocephalus by site
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Adzick NS, Thom EA, Spong CY, Brock JW 3rd, Burrows PK, Johnson MP, et al.: A randomized trial of prenatal versus postnatal repair of myelomeningocele. N Engl J Med 364:993–1004, 2011 - PMC - PubMed
    1. Bowman RM, Boshnjaku V, McLone DG: The changing incidence of myelomeningocele and its impact on pediatric neurosurgery: a review from the Children’s Memorial Hospital. Childs Nerv Syst 25:801–806, 2009 - PubMed
    1. Chakraborty A, Crimmins D, Hayward R, Thompson D: Toward reducing shunt placement rates in patients with myelomeningocele. J Neurosurg Pediatr 1:361–365, 2008 - PubMed
    1. Johnson MP, Sutton LN, Rintoul N, Crombleholme TM, Flake AW, Howell LJ, et al.: Fetal myelomeningocele repair: short-term clinical outcomes. Am J Obstet Gynecol 189:482–487, 2003 - PubMed
    1. Laskay NMB, Arynchyna AA, McClugage SG 3rd, Hopson B, Shannon C, Ditty B, et al.: A comparison of the MOMS trial results to a contemporaneous, single-institution, postnatal closure cohort. Childs Nerv Syst 33:639–646, 2017 - PMC - PubMed